Corvus Pharmaceuticals Inc

Compare

640 Followers

CRVS Stock Chart & Stats

$7.68

-$0.10(-1.74%)

At close: Jan 08 4:00 PM EST

$7.68

-$0.10(-1.74%)

Day’s Range― - ―

52-Week Range$2.54 - $10.00

Previous CloseN/A

Volume202.27K

Average Volume (3M)977.79K

Market Cap

$572.27M

Enterprise Value$237.77M

Total Cash (Recent Filing)$74.41M

Total Debt (Recent Filing)$1.08M

Price to Earnings (P/E)―

Beta1.23

Next Earnings

Nov 04, 2025

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding74,514,040

10 Day Avg. Volume1,055,828

30 Day Avg. Volume977,786

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.42

Enterprise Value/Revenue2.70K

Enterprise Value/Gross Profit-8.81K

Enterprise Value/Ebitda-6.70

Forecast

1Y Price Target

$13.75

Price Target Upside79.04% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical Program AdvancementCorvus Pharmaceuticals is advancing its atopic dermatitis clinical program and is ready to move soquelitinib into a Phase 2 study following strong results.

Regulatory ExpansionThe company's partner in China, Angel Pharmaceuticals, has received regulatory clearance to initiate a Phase 1/2 study in China, expanding the geographical scope of clinical testing.

Study Design ConfidenceThe company has modified the study design to include an expansion cohort of additional patients treated with 200 mg BID dose, indicating confidence in the drug's efficacy.

Bears Say

Corvus Pharmaceuticals News

Corvus Pharmaceuticals price target raised to $13 from $11 at Mizuho

Mizuho raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $13 from $11 and keeps an Outperform...

2d ago

CRVS

Corvus Pharmaceuticals initiated with an Overweight at Barclays

Barclays initiated coverage of Corvus Pharmaceuticals (CRVS) with an Overweight rating and $16 price target The firm launched...

18d ago

CRVS

CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Corvus Pharmaceuticals Inc. (CRVS) is scheduled to report 3rd quarter earnings on 10/30/2025. Regarding Q3 estimates, Wall Street...

3d ago

CRVS

Corvus Pharmaceuticals’ Soquelitinib Study: A Potential Game-Changer for Atopic Dermatitis

Corvus Pharmaceuticals Inc. (($CRVS)) announced an update on their ongoing clinical study. Corvus Pharmaceuticals Inc. is conducting a...

3d ago

CRVS

Corvus Pharmaceuticals’ Phase 3 Study on Soquelitinib: A Potential Game-Changer in Lymphoma Treatment

Corvus Pharmaceuticals Inc. (($CRVS)) announced an update on their ongoing clinical study. Study Overview: Corvus Pharmaceuticals Inc. is...

3d ago

CRVS

Corvus Pharmaceuticals Appoints David Moore as Director

Corvus Pharmaceuticals ( ($CRVS) ) just unveiled an announcement. On October 2, 2025, Corvus Pharmaceuticals appointed David Moore...

28d ago

CRVS

Corvus Pharmaceuticals’ Earnings Call Highlights Progress

Corvus Pharmaceuticals Inc. (($CRVS)) has held its Q2 earnings call. Read on for the main highlights of the...

3M ago

CRVS

Corvus Pharmaceuticals’ Clinical Advancements and Strategic Collaborations Boost Investor Confidence

H.C. Wainwright analyst Sean Lee CFA maintained a Buy rating on Corvus Pharmaceuticals today and set a price...

3M ago

CRVS

Corvus Pharmaceuticals price target lowered to $15 from $17 at Oppenheimer

Oppenheimer analyst Jeff Jones lowered the firm’s price target on Corvus Pharmaceuticals (CRVS) to $15 from $17 and...

3M ago

CRVS

Corvus Pharmaceuticals Reports Q2 2025 Progress and Financials

Corvus Pharmaceuticals Inc. ( ($CRVS) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

CRVS

Corvus Pharmaceuticals reports Q2 EPS (10c), consensus (12c)

“We are excited by the data reported from our Phase 1 trial of soquelitinib for atopic dermatitis and...

3M ago

CRVS

Corvus Pharmaceuticals’ Promising Study on Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Inc. (($CRVS)) announced an update on their ongoing clinical study. Corvus Pharmaceuticals Inc. is conducting a...

4M ago

CRVS

Corvus announces IND application approved by CDE of China NMPA to start trial

Corvus Pharmaceuticals (CRVS) announced that the IND application submitted by its partner in China, Angel Pharmaceuticals, has been...

4M ago

CRVS

Corvus Pharmaceuticals Holds Annual Stockholders Meeting

Corvus Pharmaceuticals ( ($CRVS) ) has provided an update. On June 12, 2025, Corvus Pharmaceuticals held its Annual...

5M ago

CRVS

CRVS FAQ

What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?

Corvus Pharmaceuticals Inc lowest stock price was $2.54 and its highest was $10.00 in the past 12 months.

What is Corvus Pharmaceuticals Inc’s market cap?

Corvus Pharmaceuticals Inc’s market cap is $572.27M.

When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?

Corvus Pharmaceuticals Inc’s upcoming earnings report date is Nov 04, 2025 which is in 4 days.

How were Corvus Pharmaceuticals Inc’s earnings last quarter?

Corvus Pharmaceuticals Inc released its earnings results on Aug 07, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.033.

Is Corvus Pharmaceuticals Inc overvalued?

According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Corvus Pharmaceuticals Inc pay dividends?

Corvus Pharmaceuticals Inc does not currently pay dividends.

What is Corvus Pharmaceuticals Inc’s EPS estimate?

Corvus Pharmaceuticals Inc’s EPS estimate is -0.13.

How many shares outstanding does Corvus Pharmaceuticals Inc have?

Corvus Pharmaceuticals Inc has 74,514,040 shares outstanding.

What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?

Corvus Pharmaceuticals Inc reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went up 4.358%.

Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in CRVS

Corvus Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-68.67%

Trailing 12-Months

Asset Growth

38.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals (CRVS) is a biotechnology company focused on the development and commercialization of innovative immuno-oncology therapies. The company is engaged in the research and development of novel drugs designed to harness the immune system to treat cancer. Corvus Pharmaceuticals' core product pipeline includes small molecule and antibody therapies targeting various immune checkpoints and pathways crucial for cancer treatment.

Corvus Pharmaceuticals (CRVS) Earnings & Revenues

Historic Earnings Reports

CRVS Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant clinical progress, particularly with soquelitinib, and a strong cash position, offset by increased net loss and R&D expenses. The positive clinical data and financial stability indicate a promising outlook despite financial challenges.View all CRVS earnings summaries

CRVS Stock 12 Month Forecast

Average Price Target

$13.75

▲(79.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","5":"$5","9":"$9","13":"$13","17":"$17"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5,9,13,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.26,7.932307692307692,8.604615384615384,9.276923076923076,9.94923076923077,10.62153846153846,11.293846153846154,11.966153846153846,12.638461538461538,13.31076923076923,13.983076923076922,14.655384615384616,15.327692307692308,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.26,7.759230769230769,8.258461538461539,8.757692307692308,9.256923076923076,9.756153846153847,10.255384615384616,10.754615384615384,11.253846153846155,11.753076923076923,12.252307692307692,12.751538461538463,13.250769230769231,{"y":13.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.26,7.547692307692308,7.835384615384616,8.123076923076923,8.41076923076923,8.698461538461538,8.986153846153845,9.273846153846154,9.561538461538461,9.849230769230768,10.136923076923077,10.424615384615384,10.712307692307693,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >